Efficacy of JOINS Tablet for Lumbar Spinal Stenosis: Prospective, Randomized, Open-Label Clinical Trial

<i>Background and Objectives</i>: Spinal stenosis, low back pain, and radiating pain to the lower extremities are caused by inflammation of the spinal canal and impaired blood flow around the nerves. Because JOINS tablets are known to have anti-inflammatory, pain-relieving, and blood circulation-enhancing properties, this research was conducted based on the assumption that they could improve spinal stenosis. <i>Materials and Methods</i>: This was a prospective, randomized, single-center, open-label clinical trial with a 6-month follow-up period. A total of 100 patients with lumbar spinal stenosis were randomized into two groups: 50 patients in the test group and 50 patients in the control group. The control group was prescribed the usual spinal stenosis medications (Naproxen, Limaprost, and Pregabalin), while the test group was prescribed JOINS tablets in addition to the usual medications. <i>Results</i>: The severity of low back pain and radiating leg pain was assessed using a Visual Analog Scale. Spinal functional outcomes were assessed using the Oswestry Disability Index (ODI) and Roland-Morris Disability Questionnaire (RMDQ), and quality of life was assessed using the Short Form 36 (SF-36), with division into Physical Component Score (PCS) and Mental Component Score (MCS). At 6 months, the JOINS group showed a greater reduction in low back pain compared with controls (<i>p</i> < 0.001). At all follow-up periods, the functional outcomes did not show statistically significant differences between the test and control groups. <i>Conclusions</i>: The significant reduction in pain suggests that JOINS tablets may be an effective adjunct for pain relief, particularly in patients at high risk of adverse effects from long-term NSAID use.